Selective JAK Inhibition in RA vs PV - Report - MDSpire

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

  • By

  • Julia Cipriano

  • February 13, 2026

  • 3 min

Share

Selective JAK Inhibition in RA vs PV

Overview

Tofacitinib demonstrated significant rheumatologic efficacy in a patient with seropositive rheumatoid arthritis and polycythemia vera, while having minimal impact on hematologic activity related to polycythemia vera. This case highlights the differential effects of JAK inhibitors across diseases driven by different JAK isoforms.

Background

The use of Janus kinase (JAK) inhibitors has become established in the treatment of autoimmune diseases like rheumatoid arthritis (RA). However, their effects can vary significantly depending on the underlying pathophysiology, particularly when JAK2 is involved, as seen in polycythemia vera (PV). Understanding these differences is crucial for optimizing treatment strategies in patients with overlapping autoimmune and myeloproliferative disorders.

Data Highlights

No numerical data available in the article.

Key Findings

  • Tofacitinib effectively induced remission of RA in a patient with concomitant PV.
  • Despite broad immunomodulatory effects, tofacitinib had limited impact on JAK2-driven erythrocytosis.
  • The patient achieved clinical and ultrasonographic remission of RA within 3 months of starting tofacitinib.
  • Hematologic parameters remained stable throughout the follow-up period.
  • After 12 months, the patient remained in RA remission without adverse events or cytopenias.

Clinical Implications

Clinicians should consider the differential effects of JAK inhibitors when treating patients with both autoimmune and myeloproliferative diseases. While tofacitinib can effectively manage RA symptoms, additional therapies targeting JAK2 may be necessary for optimal management of PV-related hematologic issues.

Conclusion

This case underscores the importance of understanding the specific actions of JAK inhibitors in different disease contexts. Further research is needed to explore the best therapeutic approaches for patients with overlapping conditions.

References

  1. Bogojevic et al, Clinical Case Reports, 2024 -- Selective JAK Inhibition in RA vs PV
  2. Drug Safety — Evaluating the Benefit-Risk Profile of Upadacitinib in Patients with Rheumatoid Arthritis: Insights from a Phase III Study Series
  3. The ASCO Post — Efficacy of a JAK2/mTOR Inhibitor Combination in Controlling Acute Graft-vs-Host Disease
  4. Drug Safety — Balancing Cardiovascular and Cancer Risks in the Use of JAK Inhibitors
  5. Clinical Rheumatology — The Role of Osteoimmunology in Rheumatoid and Psoriatic Arthritis: Investigating Tofacitinib's Impact on Bone Health
  6. Evaluating the Benefit-Risk Profile of Upadacitinib in Patients with Rheumatoid Arthritis
  7. Efficacy of a JAK2/mTOR Inhibitor Combination in Controlling Acute Graft-vs-Host Disease
  8. Balancing Cardiovascular and Cancer Risks in the Use of JAK Inhibitors
  9. https://www.eular.org/document/download/1406/ec021a77-cdf3-4de3-ae72-57c1757db549/1325
  10. https://www.besremihcp.com/wp-content/uploads/2025/08/NCCN-Flashcard-v2-2025_DIGITAL.pdf
  11. Frontiers | JAK inhibitors: an evidence-based choice of the most appropriate molecule

Original Source(s)

Selective JAK Inhibition in RA vs PV

  • by Julia Cipriano

  • February 13, 2026

Related Content

Kinesio Taping Shows Limited, Uncertain Benefits

Researchers find effects vary by timing, comparator, and outcome across musculoskeletal disorders

RA-ILD: Tracking Function and CT

Conventional monitoring markers do not change before deaths in this predominantly mild cohort.

Culture Mismatch Common in Joint Infections

Multicenter study suggests variability across centers and higher mismatch in certain clinical settings.